A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
EU CTIS ID: 2025-525016-41-00
What this study is testing
To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Age ≥ 40 years
- 2. IPF diagnosis
- 3. Participants with IPF receiving locally approved antifibrotic therapies at a stable dose, or participants with IPF not receiving local standard of care
- 4. FVC ≥ 45% predicted of normal
- 5. DLCO corrected for hemoglobin ≥ 25% predicted of normal
You likely can't join if
- 1. ILD other than IPF
- 2. The extent of emphysema is greater than the extent of fibrotic changes on chest HRCT scan
- 3. Acute exacerbation of IPF
- 4. Lower respiratory tract infection requiring treatment
- 5. Acute coronary syndrome/acute myocardial infarction, unstable angina ± coronary intervention with Percutaneous Coronary Intervention, or Coronary Artery Bypass Grafting
- 6. Heart failure
See the full eligibility criteria
- 1. Age ≥ 40 years
- 2. IPF diagnosis
- 3. Participants with IPF receiving locally approved antifibrotic therapies at a stable dose, or participants with IPF not receiving local standard of care
- 4. FVC ≥ 45% predicted of normal
- 5. DLCO corrected for hemoglobin ≥ 25% predicted of normal
- 1. ILD other than IPF
- 2. The extent of emphysema is greater than the extent of fibrotic changes on chest HRCT scan
- 3. Acute exacerbation of IPF
- 4. Lower respiratory tract infection requiring treatment
- 5. Acute coronary syndrome/acute myocardial infarction, unstable angina ± coronary intervention with Percutaneous Coronary Intervention, or Coronary Artery Bypass Grafting
- 6. Heart failure
- 7. History of organ transplantation or is likely to receive lung transplantation
The study team makes the final eligibility decision.
Where it's taking place
- Poland
- Hungary
- Netherlands
- Germany
- Greece
- Bulgaria
- Italy
- France
- Denmark
- Korea, Republic of
- South Africa
- China
- Canada
- Japan
- Chile
- Argentina
- United Kingdom
- Israel
- Mexico
- Taiwan
+ 2 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Poland; Hungary; Netherlands; Germany; Greece; Bulgaria and 16 more locations. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from EU CTIS. The study team decides eligibility, and your own doctor gives medical advice.